251. Postextrasystolic Blood Pressure Potentiation Predicts Poor Outcome of Cardiac Patients
- Author
-
Alexander Hapfelmeier, Gerd Hasenfuss, Georg Schmidt, Karl-Ludwig Laugwitz, Ralf J. Dirschinger, Petra Barthel, Michael Dommasch, Katharina M. Huster, Alexander Müller, Marek Malik, Adrian Morley-Davies, Daniel Sinnecker, St George's Hospital Medical School, and British Heart Foundation
- Subjects
Male ,Cardiac Complexes, Premature ,Cardiac & Cardiovascular Systems ,Myocardial Infarction ,Blood Pressure ,030204 cardiovascular system & hematology ,Electrocardiography ,0302 clinical medicine ,calcium cycling ,myocardial infarction ,risk assessment ,Risk Factors ,CONTRACTION ,FAILURE ,Prospective Studies ,Myocardial infarction ,Prospective cohort study ,Original Research ,RISK ,0303 health sciences ,education.field_of_study ,Ejection fraction ,medicine.diagnostic_test ,Stroke volume ,Middle Aged ,Ventricular Premature Complexes ,Cardiology ,Female ,PHOSPHOLAMBAN ,Cardiology and Cardiovascular Medicine ,Life Sciences & Biomedicine ,ACUTE MYOCARDIAL-INFARCTION ,medicine.medical_specialty ,Population ,03 medical and health sciences ,Internal medicine ,medicine ,INTERVAL ,Humans ,HEART-RATE TURBULENCE ,education ,Aged ,030304 developmental biology ,Heart Failure ,Science & Technology ,business.industry ,Stroke Volume ,medicine.disease ,Blood pressure ,Heart failure ,Cardiovascular System & Cardiology ,OVEREXPRESSION ,business - Abstract
Background Postextrasystolic blood pressure potentiation (PESP), the pulse wave augmentation after an extrasystolic beat, is typically enhanced in heart failure (HF) patients. This study prospectively tested the association of PESP and mortality in cardiac patients. Methods and Results Consecutive patients (n=941; mean age, 61 years; 19% female) presenting with acute myocardial infarction were enrolled between May 2000 and March 2005 and followed up until August 2010. The main study outcome was 5‐year all‐cause mortality. Patients underwent noninvasive 30‐minute recordings of ECG and continuous blood pressure. PESP presence was based on the ratio between the first postectopic pulse wave amplitude and the mean of the subsequent 9 pulse wave amplitudes. A ratio above 1 was prospectively defined as PESP present. Ventricular premature complexes (VPCs) suitable for PESP quantification were present in recordings of 220 patients. PESP was present in 62 of these patients. Patients without suitable VPCs were classified as PESP absent. During the follow‐up, 72 patients died. Among the 220 patients in whom PESP was measurable, 27 died. Under univariable analysis, PESP was a significant predictor of death ( P P P P P P P =0.001) were independently associated with outcome. The combination of PESP presence and LVEF ≤35% identified a subgroup of patients with a particularly high mortality of 46.7%. Separate validation reproduced the finding in an unrelated population of 146 HF patients. Conclusions PESP, which likely reflects abnormalities of myocardial calcium cycling, predicts the mortality risk in postinfarction patients. Clinical Trial Registration URL: ClinicalTrials.gov . Unique identifier: NCT00196274.
- Published
- 2014
- Full Text
- View/download PDF